A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 13 Oct 2017 Status changed from active, no longer recruiting to completed.
- 07 Oct 2017 This trial has been completed in Germany (end date: 14 Jul 2017).
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.